Search
for
Sort by
Research 151–180 of 312
- Patterns of Care for Newly Diagnosed Benign Prostatic Hyperplasia in the United States
- Off-label prescriptions: patient safety first
- Medications Most Commonly Associated With Erectile Dysfunction: Evaluation of the Food and Drug Administration National Pharmacovigilance Database
- Re: Can Long-Term LUTS/BPH Pharmacological Treatment Alter the Outcomes of Surgical Intervention?
- Editorial Comment
- Characterization and Management of Androgenetic Alopecia in Transgender and Gender-Diverse Individuals: A Narrative Review
- Oral finasteride use and sexual adverse events: signal detection from disproportionality analyses of data from the United States Food and Drug Administration Adverse Event Reporting System
- Frontal Fibrosing Alopecia in Men: A Review of the Literature
- Frontal Fibrosing Alopecia in Men: A Review of the Literature
- Medical management of benign prostatic hyperplasia
- Finasteride and Dutasteride for the Treatment of Male Androgenetic Alopecia: A Review of Efficacy and Reproductive Adverse Effects
- Síndrome postfinasterida y disfunción eréctil. Caso clínico y revisión de la literatura
- Finasteride and Its Potential for the Treatment of Female Pattern Hair Loss: Evidence to Date
- Alopecia fibrosante frontal
- Editorial Comment
- US Food and Drug Administration Warning Regarding Finasteride and Suicidal Ideation: What Should Urologists Know?
- Post-Finasteride Syndrome (PFS) Update: Point/Counterpoint
- Post-finasteride syndrome – does it really exist?
- Why Odds Ratios Can Be Tricky Statistics
- Retrospective Pharmacotherapeutic Evaluation of Dutasteride not Approved by US FDA for Androgenetic Alopecia in Korea
- Using 5 alpha reductase inhibitors safely: What primary care physicians need to know
- 5α-Reductase Inhibitors and Chemoprevention: The PCPT and Beyond
- BPH Medications May Increase Risk of Self-Harm, Depression
- Post-Finasteride Syndrome. Literature Review
- Signal Detection of Depression and Suicidality Associated with Finasteride and Dutasteride: Updated Pharmacovigilance Evidence and Recommendations for Comprehensive Psychiatric Assessment
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Investigation of the Plausibility of 5-Alpha-Reductase Inhibitor Syndrome
- Most recent findings of curative drugs for lower urinary tract symptoms in clinical practice
- Impact of Microbial Infection on Sperm Parameters of Seminal Bacteria in Asymptomatic Subfertile Males